Fanni Kleinert
Overview
Explore the profile of Fanni Kleinert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
2
Citations
2
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, et al.
Blood
. 2025 Jan;
PMID: 39883943
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total,...
2.
Furstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, et al.
Blood
. 2024 Apr;
144(3):272-282.
PMID: 38620072
The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)-guided triple combination of acalabrutinib, venetoclax, and obinutuzumab after optional bendamustine debulking in 45 patients with relapsed/refractory chronic lymphocytic leukemia...
3.
Heger J, dHargues Y, Kleinert F, Mattlener J, Weiss J, Franzen F, et al.
Eur J Haematol
. 2024 Feb;
112(6):957-963.
PMID: 38369814
Although several promising approaches for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients will ultimately achieve long-term responses. Circulating tumor...